HIV Vaccine Update: R&D Innovation Critical in the Wake of Recent Setbacks

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Understanding the Need for Vaccination Against HIV
  • The Virus
  • The Immune Response
  • The Need for an HIV Vaccine
• Market Potential of an HIV Vaccine
• Challenges and Strategic Considerations in Developing an HIV Vaccine
• Current Approaches to Vaccine Design
  • Neutralizing Antibodies
  • Cell-Mediated Immunity
• Current Vaccine Candidates
  • Recombinant Viral Vectors
    • Adenoviral Vectors
    • Canarypox Vectors
    • Modifi ed Vaccinia Vectors
    • Fowlpox Viral Vectors
  • DNA Vaccines
  • Recombinant Proteins
  • Peptides and Lipopeptides
• Future Approaches to Vaccine Design
  • Harnessing Mucosal Immunity
  • Recombinant Vectors
  • Virus-Like Particles
  • Live, Attenuated Vaccines
  • Whole, Inactivated Viral Vaccines
  • Synthetic Peptide Immunogens
  • Gene Therapy
  • Antisense Oligonucleotides
• Outlook
  • Outlook for Large Pharmaceutical Companies
  • Outlook for Biotechnology Companies
  • Role of Philanthropic Organizations

Sidebars

• Heterologous Prime-Boost Approach
• Adjuvants

Tables

• 1. HIV Proteins and Their Functions
• 2. Recombinant Vector HIV Vaccines in Development, 2007
• 3. DNA HIV Vaccines in Development, 2007
• 4. Recombinant Protein HIV Vaccines in Development, 2007
• 5. Peptide and Lipopeptide HIV Vaccines in Development, 2007
• 6. Mucosal Adjuvants in Development for Use with HIV Vaccines

Figures

• 1. Human Immunodefi ciency Virus Structure
• 2. Distribution of Worldwide Prevalent Cases of HIV, 2006